Eastern Bank
ABUS icon

Eastern Bank’s Arbutus Biopharma ABUS Stock Holding History

Eastern Bank’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.9K Hold
5,000
– – ﹤0.01% 766
2026
Q2 		$24K Hold
5,000
– – ﹤0.01% 739
2026
Q1 		$22.5K Hold
5,000
– – ﹤0.01% 698
2025
Q4 		$24K Hold
5,000
– – ﹤0.01% 695
2025
Q3 		$22.7K Hold
5,000
– – ﹤0.01% 700
2025
Q2 		$15.4K Hold
5,000
– – ﹤0.01% 709
2025
Q1 		$17.4K Hold
5,000
– – ﹤0.01% 712
2024
Q4 		$16.4K Hold
5,000
– – ﹤0.01% 720
2024
Q3 		$19.2K Buy
+5,000
New +$19.2K ﹤0.01% 687

Other funds holding ABUS

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Ledgewood Wealth Advisors
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
Premier Path Wealth Partners
Premier Path Wealth Partners Madison, New Jersey $856M AUM 23.55% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Eastern Bank's ABUS Position: Q3 2026 in Review

Eastern Bank held its Arbutus Biopharma (ABUS) position steady in Q3 2026 at 5,000 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Eastern Bank first reported a position in ABUS in Q3 2024 and has held it in 9 quarters since. The position peaked at $24K in Q4 2025. 19 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Eastern Bank held 5,000 shares of Arbutus Biopharma worth $23.9K as of Q3 2026.
  • Eastern Bank left its Arbutus Biopharma share count unchanged in Q3 2026.
  • Arbutus Biopharma made up ﹤0.01% of Eastern Bank's portfolio in Q3 2026, its #766 holding.
  • Eastern Bank first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 9 quarters since.
  • Eastern Bank's Arbutus Biopharma position peaked at $24K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Eastern Bank's 13F filing for Q3 2026, filed 5 Oct 2026.